Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DOVA
CUSIPN/A
Phone919-748-5975
Debt
Debt-to-Equity RatioN/A
Current Ratio35.32
Quick Ratio35.32
Price-To-Earnings
Trailing P/E Ratio-23.65
Forward P/E Ratio-15.22
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.38 per share
Price / Book13.95
Profitability
EPS (Most Recent Fiscal Year)($1.40)
Net Income$-29,950,000.00
Net MarginsN/A
Return on Equity-61.19%
Return on Assets-43.40%
Miscellaneous
Employees33
Outstanding Shares28,190,000
Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions
What is Dova Pharmaceuticals' stock symbol?
Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."
How were Dova Pharmaceuticals' earnings last quarter?
Dova Pharmaceuticals Inc (NASDAQ:DOVA) posted its earnings results on Wednesday, May, 9th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.47) by $0.05. View Dova Pharmaceuticals' Earnings History.
What price target have analysts set for DOVA?
4 brokers have issued 1 year target prices for Dova Pharmaceuticals' shares. Their predictions range from $29.00 to $35.00. On average, they expect Dova Pharmaceuticals' stock price to reach $32.25 in the next year. View Analyst Ratings for Dova Pharmaceuticals.
Who are some of Dova Pharmaceuticals' key competitors?
Some companies that are related to Dova Pharmaceuticals include Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Horizon Pharma (HZNP), Blueprint Medicines (BPMC), Portola Pharmaceuticals (PTLA), Ascendis Pharma A/S (ASND), TESARO (TSRO), The Medicines (MDCO), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK), Clovis Oncology (CLVS) and Intercept Pharmaceuticals (ICPT).
Who are Dova Pharmaceuticals' key executives?
Dova Pharmaceuticals' management team includes the folowing people:
- Mr. Alexander C. Sapir, Pres, CEO & Director (Age 51)
- Dr. Lee F. Allen, Chief Medical Officer (Age 66)
- Mr. Mark W. Hahn, Chief Financial Officer (Age 55)
- Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 40)
When did Dova Pharmaceuticals IPO?
(DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO.
Has Dova Pharmaceuticals been receiving favorable news coverage?
Media stories about DOVA stock have trended somewhat positive on Monday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dova Pharmaceuticals earned a news sentiment score of 0.08 on Accern's scale. They also assigned news stories about the company an impact score of 45.95 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Dova Pharmaceuticals' major shareholders?
Dova Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include PERCEPTIVE ADVISORS LLC (10.30%), BlackRock Inc. (2.30%), Nexthera Capital LP (2.02%), Wells Fargo & Company MN (1.20%), Pier Capital LLC (0.77%) and GW&K Investment Management LLC (0.51%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.
Which major investors are buying Dova Pharmaceuticals stock?
DOVA stock was purchased by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, venBio Select Advisor LLC, Nexthera Capital LP, Candriam Luxembourg S.C.A., BlackRock Inc., Citigroup Inc., Pier Capital LLC and Wells Fargo & Company MN. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.
How do I buy shares of Dova Pharmaceuticals?
Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dova Pharmaceuticals' stock price today?
One share of DOVA stock can currently be purchased for approximately $33.19.
How big of a company is Dova Pharmaceuticals?
Dova Pharmaceuticals has a market capitalization of $897.88 million. The company earns $-29,950,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Dova Pharmaceuticals employs 33 workers across the globe.
How can I contact Dova Pharmaceuticals?
Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]
MarketBeat Community Rating for Dova Pharmaceuticals (DOVA)
MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
